Algert Global LLC Acquires Shares of 39,650 DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

Algert Global LLC acquired a new stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 39,650 shares of the medical instruments supplier’s stock, valued at approximately $753,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Pacer Advisors Inc. lifted its holdings in DENTSPLY SIRONA by 15,105.1% during the 4th quarter. Pacer Advisors Inc. now owns 4,503,591 shares of the medical instruments supplier’s stock worth $85,478,000 after purchasing an additional 4,473,972 shares in the last quarter. Nuance Investments LLC boosted its stake in DENTSPLY SIRONA by 25.0% in the 4th quarter. Nuance Investments LLC now owns 13,545,981 shares of the medical instruments supplier’s stock worth $257,103,000 after purchasing an additional 2,708,097 shares during the period. Norges Bank bought a new position in DENTSPLY SIRONA in the 4th quarter worth about $45,730,000. AQR Capital Management LLC boosted its stake in DENTSPLY SIRONA by 245.1% in the 4th quarter. AQR Capital Management LLC now owns 2,893,023 shares of the medical instruments supplier’s stock worth $54,389,000 after purchasing an additional 2,054,767 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in DENTSPLY SIRONA by 18.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,549,242 shares of the medical instruments supplier’s stock worth $238,186,000 after purchasing an additional 1,975,404 shares during the period. 95.70% of the stock is owned by institutional investors.

DENTSPLY SIRONA Stock Performance

Shares of NASDAQ XRAY opened at $15.81 on Monday. The stock has a market cap of $3.15 billion, a price-to-earnings ratio of -7.64, a P/E/G ratio of 1.80 and a beta of 0.92. The company has a current ratio of 1.25, a quick ratio of 0.84 and a debt-to-equity ratio of 0.72. DENTSPLY SIRONA Inc. has a 1-year low of $12.16 and a 1-year high of $28.69. The stock’s 50-day moving average is $14.36 and its 200 day moving average is $17.54.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.14. The company had revenue of $879.00 million for the quarter, compared to analysts’ expectations of $854.75 million. DENTSPLY SIRONA had a positive return on equity of 12.62% and a negative net margin of 10.59%. DENTSPLY SIRONA’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period last year, the firm posted $0.42 EPS. On average, sell-side analysts anticipate that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 11th. Investors of record on Friday, March 28th were issued a dividend of $0.16 per share. The ex-dividend date was Friday, March 28th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 4.05%. DENTSPLY SIRONA’s dividend payout ratio is -14.10%.

Insider Buying and Selling

In related news, Director Gregory T. Lucier purchased 15,142 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, March 3rd. The shares were acquired at an average cost of $16.51 per share, for a total transaction of $249,994.42. Following the transaction, the director now directly owns 81,971 shares in the company, valued at $1,353,341.21. The trade was a 22.66% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have commented on XRAY shares. Wells Fargo & Company cut their target price on DENTSPLY SIRONA from $20.00 to $19.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. UBS Group cut their target price on DENTSPLY SIRONA from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Friday. StockNews.com upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research note on Friday. Morgan Stanley cut DENTSPLY SIRONA from an “overweight” rating to an “equal weight” rating and set a $14.00 price target on the stock. in a report on Tuesday, April 15th. Finally, Mizuho lowered their price target on DENTSPLY SIRONA from $21.00 to $18.00 and set a “neutral” rating on the stock in a report on Thursday, March 13th. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $20.27.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.